Metoprolol vs Carvedilol for Kidney Disease Patients
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
Recruiting
Phase 3
Interventional Study
End-Stage Kidney Disease
End-Stage Renal Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 2,540 (estimated)
- Sponsor
- VA Office of Research and Development · Federal
Who this trial is looking for
This trial is looking for patients on hemodialysis who take certain beta blockers. Participants will receive either metoprolol or carvedilol to see how these medications affect heart health.
Are You a Good Fit for This Trial?
You may be able to join if
- I am on hemodialysis
- I have received metoprolol, atenolol, labetalol, carvedilol, or bisoprolol
You may not be able to join if
- I have impaired decision-making capacity
- I have asthma and I am not taking carvedilol
- I have a known allergy to either medication
- My doctor is not willing to prescribe a new medication for me
- I cannot provide surrogate consent
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will a…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* On hemodialysis
* Received one of the following beta blockers through the VA pharmacy: metoprolol (succinate or tartrate), atenolol, labetalol, carvedilol, bisoprolol
Exclusion Criteria:
* Impaired decision-making capacity
* Patients not receiving carvedilol who have a histo…
Contacts